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Abstract
Background: Obesity is a disease that is caused by genetic and environmental factors. However, epigenetic mechanisms
of obesity are less well known. DNA methylation provides a mechanism whereby environmental factors can influence
gene transcription. The aim of our study was to investigate skeletal muscle DNA methylation of sorbin and SH3 domain
containing 3 (SORBS3) with weight loss induced by Roux-en-Y gastric bypass (RYGB).
Results: Previously, we had shown increased methylation (5.0 to 24.4%) and decreased gene expression (fold change
− 1.9) of SORBS3with obesity (BMI > 30 kg/m2) compared to lean controls. In the present study, basal muscle biopsies
were obtained from seven morbidly obese (BMI > 40 kg/m2) female subjects pre- and 3 months post-RYGB surgery, in
combination with euglycemic-hyperinsulinemic clamps to assess insulin sensitivity. We identified 30 significantly
altered promoter and untranslated region methylation sites in SORBS3 using reduced representation bisulfite sequencing
(RRBS). Twenty-nine of these sites were decreased (− 5.6 to − 24.2%) post-RYGB compared to pre-RYGB. We confirmed the
methylation in 2 (Chr.8:22,423,690 and Chr.8:22,423,702) of the 29 decreased SORBS3 sites using pyrosequencing. This
decreased methylation was associated with an increase in SORBS3 gene expression (fold change + 1.7) post-surgery. In
addition, we demonstrated that SORBS3 promoter methylation in vitro significantly alters reporter gene expression (P < 0.
0001). Two of the SORBS3 methylation sites (Chr.8:22,423,111 and Chr.8:22,423,205) were strongly correlated with fasting
plasma glucose levels (r = 0.9, P = 0.00009 and r = 0.8, P = 0.0010). Changes in SORBS3 gene expression post-surgery were
correlated with obesity measures and fasting insulin levels (r = 0.5 to 0.8; P < 0.05).
Conclusions: These results demonstrate that SORBS3 methylation and gene expression are altered in obesity
and restored to normal levels through weight loss induced by RYGB surgery.
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Background
One third of the US adult population is obese (body
mass index [BMI] > 30 kg/m2), and the number of indi-
viduals entering into morbid obesity (BMI > 40 kg/m2)
is on the rise [1, 2]. Roux-en-Y gastric bypass (RYGB) is
one of the most common surgeries performed to treat
obesity and combines restrictive and malabsorptive tech-
niques [3]. Besides weight loss, other benefits of surgical
intervention have included improved blood glucose
levels and insulin sensitivity and secretion [3–5]. How-
ever, these studies do not completely explain the mo-
lecular basis of the metabolic improvements observed
with weight loss induced by surgery.
One of the most studied epigenetic marks is DNA
methylation, which is the addition of a methyl group to
the fifth carbon of a cytosine, typically preceding a guan-
ine, termed CpG dinucleotide [6]. The addition or removal
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of these marks has regulatory influence on gene expres-
sion [7]. Our previously published study identified a novel
gene, sorbin and SH3 domain containing 3 (SORBS3), that
was differentially methylated with obesity [8]. Specifically,
we had shown an increase in skeletal muscle promoter
methylation and a decrease in mRNA expression of
SORBS3 with obesity [8]. The SORBS3 gene codes for the
adapter protein vinexin and has been shown to play a role
in growth-factor-induced signal transduction and cyto-
skeleton structure [9]. We have previously proposed a
model where chronic inflammation from obesity may lead
to insulin resistance by inducing changes to the extracellu-
lar matrix that are reminiscent of fibrosis and alter
mechanosignal transduction mediated by cytoskeletal ele-
ments [10]. We believe that changes in SORBS3 expres-
sion may be connected to our proposed model since it is a
cytoskeletal gene that was reduced with obesity [8]. How-
ever, it is unclear whether the reduction in SORBS3 ob-
served in obesity could be rescued through surgical
weight-loss interventions such as RYGB.
Here, we set out to determine if the changes in
SORBS3 DNA methylation identified in obesity and its
underlying insulin resistance can be altered in response
to weight loss, using our previously described RYGB sur-
gery cohort [11]. We hypothesized that 3 months post-
surgery, SORBS3 methylation would be decreased and
this would result in an increased gene expression, so it
would be normalized to levels observed in lean controls.
Methods
Study design
Seven (one of which was diabetic, treated with metformin)
morbidly obese (BMI > 40 kg/m2) females (ages 33–
59 years) participated in this study pre- and 3 months
post-RYGB surgery. The study was approved by the insti-
tutional review boards at the Mayo Clinic in Arizona and
Arizona State University. The design of this study and sur-
gical procedure have been previously described [11].
Muscle biopsy processing
Genomic DNA and total RNA were isolated from
muscle biopsies as previously described [8].
Reduced representation bisulfite sequencing (RRBS)
RRBS sample preparation was performed on the pre-
and 3-month post-surgery DNA by the Mayo Clinic
Genotyping Shared Resource facility. The RRBS sample
preparation has been described in detail elsewhere [8].
Sequence data was processed using the streamlined ana-
lysis and annotation pipeline for reduced representation
bisulfite sequencing, SAAP-RRBS [8, 12].
Differentially methylated cytosine (DMC) analysis pre- and
post-surgery
Differences in methylation sites were assessed in partici-
pants pre- and post-surgery. The aligned (Hg19) sequen-
cing data was imported into the free open source R
package, methylSig [13]. A minimum of five reads and
the recovery of the site in all seven participants from
pre- and post-surgery were required for the inclusion of
a cytosine in subsequent analyses. The mean methyla-
tion differences (%) were determined and annotations
were applied, as previously described [8]. DMCs within
the promoter and untranslated regions for SORBS3 were
extracted from the data set.
SORBS3 pyrosequencing
DNA methylation sites were confirmed using pyrosequenc-
ing, as previously described [8]. To assess SORBS3 DMCs
at positions Chr.8:22,423,519 and Chr.8:22,423,529 on the
sense strand, bisulfite-converted DNA was amplified by
PCR using the following primers: forward 5′-AGTAG
GGGGAGGAAGGAA-3′ and biotinylated reverse 5′-ACC
CCCATCCTCTACTAAAAATTAAC-3′. For the DMCs at
positions Chr.8:22,423,690 and Chr.8:22,423,702 on the
antisense strand, bisulfite-converted DNA was amplified by
PCR using the following primers: forward 5′-GGGTT
TTGGGTTTTTTATAGGATG-3′ and biotinylated reverse
5′- CCACCCAAAACAACTAACTCCTAAC-3′. Pyrose-
quencing was performed using the PyroMark Q96 MD sys-
tem and the Gold Q96 kit with sequencing primers for the
sense 5′-GGGGGAGGAAGGAAT-3′ and antisense 5′-
TGGGTTTTTTATAGGATGT-3′ strands according to the
manufacturer’s instructions (Qiagen, Valencia, CA). Se-
quence analysis was performed using the PyroMark CpG
SW 1.0 software (Qiagen, Valencia, CA).
SORBS3 quantitative real-time PCR (qRT-PCR)
Gene expression for SORBS3 pre- and post-surgery was
detected using qRT-PCR on the ABI PRISM 7900HT se-
quence detection system (Life Technologies, Carlsbad,
CA). The qRT-PCR analyses of the samples were per-
formed using the TaqMan primer and probes as previ-
ously described [8].
Luciferase assay
An 811 bp fragment of the human SORBS3 promoter
(Chr8:22,422,247–22,423,057) was cloned into a CpG-
free luciferase reporter vector (pCpGL-basic). The
SORBS3 construct was either mock methylated or meth-
ylated using 1600 μM S-adenosylmethionine (SAM) and
two different DNA methyltransferases, SssI and HhaI
(New England Biolabs, Frankfurt, Germany). Mouse
muscle cell lines C2C12 were cultured in DMEM, sup-
plemented with 10% serum and 1% of an antibiotic/anti-
mycotic mixture. Cells were co-transfected with 100 ng
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of pCpGL-basic with the SORBS3 promoter insert or
without (control) and 2 ng of pRL renilla luciferase con-
trol reporter vector using the Lipofectamine 3000 trans-
fection reagent (Invitrogen, Carlsbad, CA). Firefly
luciferase activity was measured and normalized against
the renilla luciferase activity using the Dual Luciferase
Reporter Assay System (Promega, Madison, WI). The re-
sults presented are a mean of four independent experi-
ments, containing the mean of five replicates in each
experiment.
SORBS3 comparative DMC analysis
The RRBS data from our previous lean versus obese par-
ticipant study [8] was used for comparative analysis. The
data comprised of 11 lean (ages 21–43 years; 7 females/4
males; BMI 23.4 ± 2.4 kg/m2) and 9 obese (ages 32–
52 years; 4 females/5 males; BMI 32.9 ± 2.3 kg/m2)
participants.
Predictive transcription factor binding analysis
PROMO version 3.0.2 was used to perform transcription
factor binding site analysis [14]. Sequences were analyzed
with a 5% maximum matrix dissimilarity rate using
TRANSFAC version 8.3 database. Analysis of the 30
SORBS3 DMCs was assessed as 10 separate sequences:
Chr.8:22,411,723–22,411,734; Chr.8:22,422,932–22,422,973;
Chr.8:22,423,009–22,423,025; Chr.8:22,423,086–22,423,116;
Chr.8:22,423,181–22,423,215; Chr.8:22,423,219–22,423,256;
Chr.8:22,423,514–22,423,573; Chr.8:22,423,684–22,423,695;
Chr.8:22,423,697–22,423,741; and Chr.8:22,423,769–22,42
3,857.
Statistical analysis
Pre- and post-surgery comparisons were based on a
paired Student t test. All phenotypic data was normally
distributed and presented as a mean ± standard devi-
ation (SD). Pearson correlation analysis was performed
to determine the relationship between DNA methylation
from RRBS or gene expression and the phenotypic data.
A Bonferroni correction was applied to the Pearson cor-
relation analysis performed on the RRBS 30 DMCs with
the phenotype data. Therefore, for the correlation ana-
lysis of the RRBS DMCs with the phenotypic data, we
considered a P ≤ 0.0167 to be significant. For all other
correlations, we used the P ≤ 0.05 cutoff. See above
for the statistical analysis of the methylation and
qRT-PCR data.
Results
Participants
The metabolic data for these subjects have been de-
scribed in a previous publication [11]. Briefly, 3 months
post-surgery, significant improvements were observed
(Table 1) in BMI, body fat percentage, cholesterol, low-
density lipoprotein (LDL), fasting plasma glucose (FPG),
fasting serum insulin (FSI), and homeostatic model as-
sessment for insulin resistance (HOMA-IR). However,
there were no significant improvements observed in
blood pressure, triglycerides, high-density lipoprotein
(HDL), hemoglobin A1c (HbA1c), endogenous glucose
production (EGP), and insulin-stimulated glucose dis-
posal (M-value).
SORBS3 differentially methylated cytosines (DMCs)
Methylation sites within the promoter (0 to − 1000 base
pairs from transcription start site) and untranslated re-
gions (5′ and 3′UTR) were used to detect sites that may
lead to a change in SORBS3 mRNA expression. From
the RRBS, 352 CpG sites associated with SORBS3 were
captured. Of these sites, 8.5% were differentially methyl-
ated (30 DMCs). From the 30 DMCs, there were 20
DMCs in the sense strand and 10 DMCs in the antisense
strand identified (Table 2). As shown in Table 2, 29 of
the 30 sites were decreased post-RYGB. The loss of
DNA methylation post-surgery was detected specifically
for SORBS3 and was not the by-product of global losses
in methylation (mean ± standard deviation, global pre
33.9 ± 39.9% versus global post 33.7 ± 39.7%).
SORBS3 validation
Pyrosequencing was used for confirmation of the 30
SORBS3 DMCs where primers could be designed. The
SORBS3 region that we were targeting for pyrosequenc-
ing was difficult to validate. The sequence characteristics
of that region resulted in amplicons that would be too
long or would have too many CpG sites and as such re-
sulted in the failure of the assay design. Regardless, we
were able to design primers that captured the DMCs at
positions Chr.8:22,423,519 and Chr.8:22,423,529 on the
sense strand, as well as four additional CpG sites. All six
sites were trending towards a decrease in methylation
post-surgery; however, none were significant (Fig. 1a).
The sequence that encompassed the DMCs at positions
Chr.8:22,423,690 and Chr.8:22,423,702 on the antisense
strand included two additional CpG sites. All four sites
were decreased in methylation post-surgery, and changes
in three of these sites were statistically significant
(P < 0.05; Fig. 1b).
SORBS3 gene expression
The qRT-PCR results demonstrated an increase in gene
expression of SORBS3 post-surgery compared to pre-
surgery (+ 1.7 versus 1.0 fold change, respectively;
P = 0.05).
SORBS3 correlation analysis
Pearson correlation analysis was performed to determine
the relationship between the phenotypic data and
Day et al. Clinical Epigenetics  (2017) 9:96 Page 3 of 8
SORBS3 changes observed with surgery. Of the DMCs
detected using RRBS, we demonstrated two Bonferroni-
corrected significant associations with fasting plasma
glucose (FPG) at DMCs Chr.8:22,423,111 (r = 0.9,
P = 0.00009) and Chr.8:22,423,205 (r = 0.8, P = 0.0010).
Association of SORBS3 gene expression with phenotypic
data was performed using the Ct values from qRT-PCR.
Pearson’s correlation analysis identified a significant rela-
tionship between the gene expression data and BMI
(r = 0.8, P = 0.00040), percent body fat (r = 0.6,
P = 0.02), and FSI (r = 0.5, P = 0.04). Furthermore, an
association between SORBS3 gene expression and
methylation was identified at DMCs Chr.8:22,423,519
(r = 0.7, P = 0.004), Chr.8:22,423,689 (r = 0.5, P = 0.05),
and Chr.8:22,423,702 (r = 0.6, P = 0.03).
SORBS3 promoter methylation in vitro alters reporter
gene expression
The SORBS3 construct was created to test the effect of
DNA methylation on transcriptional activity. Level of
suppressed transcriptional activity, as measured by lucif-
erase activity, was determined in comparison to the
mock methylated control (Fig. 2). As shown in Fig. 2,
when the SORBS3 construct was methylated in vitro
using the HhaI enzyme (GCGC, n = 8 sites), transcrip-
tional activity was not suppressed but was significantly
suppressed with the SssI enzyme methylation (CG,
n = 59 sites).
Predicted transcription factor binding analysis
To identify potential transcription factor binding that may
be inhibited by SORBS3 methylation, we analyzed se-
quences containing DMCs using PROMO [14]. Transcrip-
tion factor binding motifs were identified to overlap 13 of
the 30 DMCs for SORBS3: Chr.8:22,422,937: AP-2alphaA;
Chr.8:22,422,953: Sp1; Chr.8:22,423,014 and 22,423,020:
GCF; Chr.8:22,423,100: CREB; Chr.8:22,423,204, 22,423,
205, 22,423,206, and 22,423,210: GCF; Chr.8:22,423,235:
Sp1, Pax-5, and p53; Chr.8:22,423,689 and 22,423,690:
GCF; and Chr.8:22,423,736: RXR-alpha.
SORBS3 alterations with obesity and RYGB surgery
Increased DNA methylation in the promoter and 5′UTR
of SORBS3 with obesity were originally identified in our
previous study [8]. In the RYGB cohort, methylation
levels of SORBS3 were found to decrease post-surgery.
Upon comparing the 10 DMCs (9 increased and 1 de-
creased) from our previous study, and the 30 DMCs (29
decreased and 1 increased) identified with RYGB sur-
gery, we found sites to cluster in the same region, but
no sites were identical between studies (Fig. 3). We
assessed the average methylation levels of all significant
DMCs regardless of directional change (Fig. 4a). More-
over, we averaged methylation levels of the significant
DMCs that were consistent in the direction of methyla-
tion change (9 increased sites were averaged from the
lean and obese study and 29 decreased sites were
Table 1 Phenotype data pre- and 3 months post-Roux-en-Y gastric bypass surgery
Pre-surgery obese Post-surgery obese P value
Pre vs. post
Sex 7 female 7 female –
Age (years) 45.1 ± 9.4 45.3 ± 9.3 NS
Body mass index (kg/m2) 42.1 ± 5.9 35.3 ± 4.9 < 0.001
Body fat (%) 46.4 ± 3.2 40.6 ± 3.4 < 0.01
Systolic blood pressure (mmHg) 125.1 ± 10.3 119.1 ± 12.2 NS
Diastolic blood pressure (mmHg) 71.7 ± 5.4 75.1 ± 4.4 NS
Triglycerides (mg/dL) 121.9 ± 46.2 107.7 ± 29.5 NS
Cholesterol (mg/dL) 181.4 ± 34.9 151.5 ± 29.6 < 0.01
High-density lipoprotein (mg/dL) 45.0 ± 7.1 45.0 ± 6.7 NS
Low-density lipoprotein (mg/dL) 112.1 ± 31.6 84.8 ± 27.8 < 0.01
Hemoglobin A1c (%) 6.0 ± 0.4 5.7 ± 0.3 NS
Fasting plasma glucose (mg/dL) 104.2 ± 20.7 86.7 ± 8.2 < 0.05
Fasting plasma insulin (μU/mL) 18.2 ± 10.1 7.5 ± 4.2 < 0.01
EGP (mg/kg/min) 1.5 ± 0.1 1.5 ± 0.1 NS
M-value (mg/kg/min) 2.4 ± 0.9 2.9 ± 1.0 NS
M-value (mg/kgFFM/min) 4.4 ± 1.7 4.9 ± 1.6 NS
HOMA-IR 4.4 ± 2.2 1.6 ± 0.9 < 0.05
Data presented as mean ± SD
HOMA-IR homeostatic model assessment for insulin resistance, EGP endogenous glucose production
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averaged for the RYGB cohort) (Fig. 4b). Both analyses
presented similar average methylation levels between the
lean and post-surgery and the obese and pre-surgery
(Fig. 4a, b).
Discussion
Our previous study had identified SORBS3 as an obesity-
associated gene, whose expression may be epigenetically reg-
ulated [8]. We set out to further establish the relationship
between SORBS3 methylation and gene expression changes
with obesity through a surgical weight-loss intervention.
Three months following the RYGB surgery, there were
significant reductions in weight and improvement of meta-
bolic measures such as BMI, percent body fat, and fasting
plasma insulin levels. However, we did not observe improve-
ments in EGP orM-value as determined by the euglycemic-
hyperinsulinemic clamp. Our observations are consistent
with others [15, 16]. EGP has been shown to significantly
decrease immediately after surgery and return to pre-
surgery measures at 3 months [15]. The M-value has been
shown to significantly improve at 12 months with major
weight loss [16]. It could be hypothesized that we may have
observed improvements in EGP and theM-value had we ex-
tended the study beyond the 3 months post-surgery.
Table 2 Differentially methylated cytosines (DMC; P < 0.05) post-surgery that were associated with SORBS3
DNA methylation (%) Total no. of reads
Chr.8 position Pre-surgery Post-surgery P value Pre-surgery Post-surgery Strand Gene region CpG island region Correlated
GE
TFBM overlap
22,411,728 16.3 ± 5.8 7.0 ± 6.0 0.03 135.0 133.0 + 5′UTR South shelf
22,411,729 6.6 ± 7.9 0.0 ± 0.0 0.005 89.0 106.0 − 5′UTR South shelf
22,422,937 19.4 ± 25.1 5.8 ± 7.8 0.04 125.0 194.0 − Promoter CpG island AP-2alphaA
22,422,940 27.8 ± 24.8 10.2 ± 12.2 0.02 125.0 194.0 − Promoter CpG island
22,422,953 35.2 ± 22.2 11.2 ± 12.4 0.003 129.0 200.0 − Promoter CpG island Sp1
22,422,968 16.5 ± 10.6 5.3 ± 8.5 0.007 129.0 200.0 − Promoter CpG island
22,423,014 21.4 ± 14.6 7.7 ± 5.6 0.003 118.0 120.0 + Promoter CpG island GCF
22,423,020 18.0 ± 7.8 7.5 ± 7.9 0.04 118.0 120.0 + Promoter CpG island GCF
22,423,091 22.4 ± 11.2 7.9 ± 6.5 0.006 119.0 120.0 + Promoter CpG island
22,423,100 17.2 ± 10.8 7.1 ± 5.7 0.03 119.0 120.0 + Promoter CpG island CREB
22,423,111 10.7 ± 12.2 1.3 ± 2.1 0.02 119.0 120.0 + Promoter CpG island
22,423,186 8.8 ± 12.5 22.4 ± 11.3 0.04 84.0 103.0 + 5′UTR CpG island
22,423,198 13.8 ± 8.7 5.0 ± 3.9 0.03 130.0 158.0 + 5′UTR CpG island
22,423,202 18.8 ± 13.2 8.8 ± 2.4 0.01 130.0 158.0 + 5′UTR CpG island
22,423,204 7.9 ± 6.0 0.0 ± 0.0 0.0001 130.0 158.0 + 5′UTR CpG island GCF
22,423,205 8.4 ± 5.4 1.9 ± 2.1 0.001 258.0 290.0 − 5′UTR CpG island GCF
22,423,206 14.7 ± 7.7 6.9 ± 4.8 0.03 130.0 158.0 + 5′UTR CpG island GCF
22,423,210 23.7 ± 11.2 14.1 ± 3.1 0.03 130.0 158.0 + 5′UTR CpG island GCF
22,423,224 13.1 ± 8.5 3.3 ± 3.9 0.001 187.0 248.0 + 5′UTR CpG island
22,423,235 17.4 ± 11.4 10.1 ± 3.0 0.04 228.0 289.0 + 5′UTR CpG island Sp1/Pax5/p53
22,423,251 18.2 ± 12.1 8.4 ± 5.4 0.04 130.0 158.0 + 5′UTR CpG island
22,423,519 28.0 ± 8.5 14.3 ± 5.8 0.002 193.0 216.0 + 5′UTR CpG island X
22,423,529 29.8 ± 6.5 17.9 ± 8.1 0.005 184.0 207.0 + 5′UTR CpG island
22,423,568 26.5 ± 9.0 16.0 ± 8.7 0.02 359.0 415.0 + 5′UTR CpG island
22,423,689 46.8 ± 9.8 31.1 ± 13.6 0.01 252.0 310.0 + 5′UTR CpG island X GCF
22,423,690 50.6 ± 6.8 38.0 ± 16.5 0.04 276.0 342.0 − 5′UTR CpG island GCF
22,423,702 38.4 ± 10.7 20.9 ± 14.5 0.007 278.0 345.0 − 5′UTR CpG island X
22,423,736 18.5 ± 5.6 11.2 ± 4.4 0.007 363.0 441.0 + 5′UTR South shore RXR-alpha
22,423,774 53.0 ± 14.2 32.1 ± 22.5 0.03 101.0 79.0 − 5′UTR South shore
22,423,852 31.2 ± 11.9 15.0 ± 12.7 0.03 92.0 73.0 − 5′UTR South shore
DNA methylation data presented as mean ± SD
GE correlated gene expression, TFBM transcription factor binding motif
Day et al. Clinical Epigenetics  (2017) 9:96 Page 5 of 8
Environmental factors can influence transcriptional
regulation through DNA methylation. Following weight
loss induced by surgery, we observed significant de-
creases in SORBS3 methylation and increased gene ex-
pression. When we applied a conservative Bonferroni
correction, we demonstrated two highly significant asso-
ciations between SORBS3 DMCs and fasting plasma glu-
cose levels. Moreover, the gene expression data was
significantly associated with BMI, percent body fat, and
fasting insulin levels. In another study, Barres et al. iden-
tified significant positive correlations between PGC1α
methylation levels and phenotypes, such as BMI and tri-
glycerides 6 months post-surgery [17]. Both the Barres
et al. study and our current study have observed that
methylation changes are correlated with metabolic phe-
notypes [17]. This observation would suggest that the
methylation changes are not contingent on the alteration
of one phenotype, but changes in an individuals’ meta-
bolic status. Collectively, our findings highlight the rela-
tionship between decreased SORBS3 DNA methylation
in the presence of weight loss induced by surgery.
The changes observed in SORBS3 DNA methylation
and gene expression complement our previous findings
[8]. Interestingly, reduced methylation and increased ex-
pression post-surgery were relatively proportional to
levels found in our lean individuals, even though the
mean BMI for these groups were not comparable. This
link between DNA methylation and gene expression
changes was further established by in vitro measures.
The luciferase assay has been used in this study and in
others [17, 18] as a reliable means of providing evidence
for the regulatory role of promoter methylation on gene
expression. Typically, with the use of multiple methyl-
transferases, a stepwise decrease in luciferase expression
is observed with an increasing number of methylated
sites [18]. We observed decreased gene expression with
the methylation set by SssI, but not with HhaI, suggest-
ing the number and positioning of the sites in that pro-
moter to be important. Coincidentally, the methylation
changes identified in the current study were only repre-
sented within the SssI methylated sites and not the HhaI.
However, the exact mechanism in which our DNA
methylation sites regulate the transcription of SORBS3
has not been elucidated. We have identified potential
transcription factor binding motifs that may be affected
by the presence of methylation, but require further in-
vestigation. Specifically, the transcription factors that
may be influenced in this assay that overlap with our
sites of interest are GC-binding factor (GCF), specificity
protein 1 (Sp1), and activating enhancer-binding protein
2-alpha (AP-2 Alpha).
The gene SORSB3 codes for the cytoskeletal adapter
protein vinexin [19]. Previously, we have shown that
cytoskeletal proteins are reduced in insulin resistance
[20]. We have proposed a model in which the reduction
in cytoskeletal elements can disrupt the sensing of con-
tractile activity, leading to altered mechanosignaling for
gene expression changes in mitochondrial biogenesis
[10]. This can potentially lead to a reduction and
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Fig. 1 Differentially methylated cytosines (DMCs) associated with SORBS3 detected using pyrosequencing on the sense strand (a) and antisense
strand (b) pre- and post-surgery. Data presented as mean ± SD
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Fig. 2 In vitro DNA methylation of the SORBS3 human promoter is
associated with decreased gene expression. Data presented as
mean ± SD. The mean represents four independent experiments
with five replicates per experiment. *P < 0.0001
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abnormal function of mitochondria and ultimately result
in cellular abnormalities (lipid accumulation, reduced fat
oxidation, and insulin signaling) related to insulin resist-
ance. It is tempting to speculate that a reduction in
vinexin abundance may play a role in the altered cyto-
skeletal organization for mechanosignal transduction
proposed with insulin resistance. Furthermore, our
current findings with weight loss induced by surgery
could ameliorate these changes associated with obesity
and insulin resistance.
Conclusions
Collectively, the post-surgery findings present an exciting
new addition to understanding the DNA methylation
changes associated with SORBS3 expression. We have previ-
ously detected differences associated with SORBS3 in indi-
viduals with obesity and insulin resistance, and the present
study provided further evidence of alterations in SORBS3 in
response to weight loss by surgical intervention. However,
we acknowledge the limitation of our sample size in the
present study. Future studies will need to confirm our find-
ings in a larger cohort. Moreover, we observed in vitro the
suppression of SORBS3 promoter DNA methylation on
transcriptional activity. The specific placement of these sites
can play an important role on the binding ability of tran-
scription factors. We identified potential transcriptional reg-
ulators overlapping our methylation sites; however, follow-
up studies will be necessary to refine the specific interaction.
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Fig. 3 Differentially methylated cytosine (DMC) distribution among the promoter and 5′ untranslated regions of sorbin and SH3 domain containing 3
(SORBS3) variants 1 and 2. The DMCs are derived from a previous study in obesity (Ln = lean vs Ob = obese) and the present RYGB cohort (bariatric)
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Fig. 4 Average methylation levels of SORBS3 DMCs from lean and obese participants in a previous study and the present study pre- and post-surgery
levels. The average methylation was assessed with all DMCs, regardless of methylation direction (a) and of only the DMCs that were consistent in the
direction of methylation (b). Data presented as mean ± SD
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